Betahistine for Rotatory and Non-Rotatory Dizziness

Introduction to Betahistine Use

• The American Academy of Otolaryngology-Head and Neck Surgery cannot make a definitive recommendation for the use of betahistine in Ménière's disease due to high-quality trials showing no benefit over placebo 1, 2

Diagnostic Criteria for Ménière's Disease

• Patients must meet diagnostic criteria for definite Ménière's disease, including two or more spontaneous episodes of rotatory vertigo lasting 20 minutes to 12 hours, audiometrically documented fluctuating low- to mid-frequency sensorineural hearing loss in the affected ear, and fluctuating aural symptoms in the affected ear 3

Contraindications and Cautions

• Betahistine is absolutely contraindicated in patients with pheochromocytoma 1, 2, 4
• Betahistine should be used with caution in patients with asthma, history of peptic ulcer disease, and other conditions 1, 2, 4

Dosing Protocol

• The recommended starting dose of betahistine is 48 mg daily, with no advantage shown for higher doses 1, 4
• Treatment should be continued for at least 3 months to evaluate efficacy, and reassessed at 6-9 months 1, 4, 2

Alternative Treatments

• For refractory Ménière's disease, consider intratympanic gentamicin, intratympanic steroids, or intratympanic steroids combined with betahistine, which have shown stronger evidence for vertigo control 1

Differential Diagnosis

• Vestibular migraine can closely mimic Ménière's disease, and should be assessed for before diagnosing Ménière's disease, looking for vertigo triggers, short or prolonged vertigo duration, visual auras, and bilateral auditory complaints 3, 5